Page 5 - Read Online

Haydu et al. J Cancer Metastasis Treat 2021;7:36 Journal of Cancer
DOI: 10.20517/2394-4722.2021.39
Metastasis and Treatment

Review Open Access

CAR T-Cell therapies in lymphoma: current
landscape, ongoing investigations, and future

directions

J. Erika Haydu, Jeremy S. Abramson
Center for Lymphoma, Massachusetts General Hospital & Harvard Medical School, Boston, MA 02114, USA.
Correspondence to: Jeremy S. Abramson, Director, Center for Lymphoma, Massachusetts General Hospital & Harvard Medical
School, 55 Fruit Street, Boston, MA 02114, USA. E-mail: jabramson@mgh.harvard.edu

How to cite this article: Haydu JE, Abramson JS. CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations,
and future directions. J Cancer Metastasis Treat 2021;7:36. https://dx.doi.org/10.20517/2394-4722.2021.39

Received: 16 Feb 2021 First Decision: 8 May 2021 Revised: 14 May 2021 Accepted: 24 May 2021 First online: 25 May 2021
Academic Editors: Francesca Montanari, Lucio Miele Copy Editor: Xi-Jun Chen Production Editor: Xi-Jun Chen

Abstract
Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with
relapsed/refractory large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, with multiple FDA-
approved CAR T products now commercially available. Ongoing studies seek to move CAR T-cells to earlier lines of
therapy and to characterize the efficacy and safety of CAR T-cell approaches in additional lymphoma histologies
including relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Other areas of active
research address CAR T in combination with other lymphoma-directed therapies, and mechanisms of CAR T
resistance. This review focuses on the FDA-approved anti-CD19 CAR T products for B-cell lymphomas,
management of CAR T-cell-associated toxicities, approaches to bridging therapy, and ongoing clinical trials and
future research directions across a broad range of lymphoma histologies.

Keywords: CAR T-cells, cell therapy, adoptive immunotherapy, non-Hodgkin lymphoma, aggressive lymphoma,
indolent lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma

INTRODUCTION
Non-Hodgkin lymphomas (NHL) comprise a heterogenous group of neoplasms arising from B- or T-
lymphocytes, with 81,560 new cases and 20,720 deaths from NHL estimated in the United States in 2021 .
[1]

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.jcmtjournal.com